BSF’s Kerato Ltd Advances Corneal Damage Treatment

BSF Enterprise PLC (GB:BSFA) has released an update.

BSF Enterprise PLC, through its subsidiary Kerato Ltd, has partnered with the University of Montreal to develop an innovative in-situ gelling cornea treatment for corneal damage, which could dramatically simplify procedures and improve patient outcomes. The new therapy will leverage tissue engineering to create a treatment that reduces hospital time, costs, and graft rejection rates, and is expected to initially be tested in veterinary cases. This aligns with Kerato’s goal to commercialize their tissue engineering intellectual property and expand into clinical and veterinary trials.

For further insights into GB:BSFA stock, check out TipRanks’ Stock Analysis page.